Document › Details

Genedata AG. (5/12/03). "Press Release: Japan’s National Cancer Center and Genedata Collaborate on Proteomics-based Cancer Diagnostic".

	Region	Japan
	Organisation	Genedata AG
	Group	Genedata (Group)
	Organisation 2	National Cancer Center (NCC) (JP)
	Person	Kaul, Adesh (Genedata 200305 Head of Marketing & Business Development)

Genedata and the National Cancer Center Japan (NCC) have entered into a collaboration for proteomics-based cancer research. Under the terms of the agreement, the NCC has licensed Genedata Impressionist™ to analyze vast amounts of 2D-protein gel data derived from Amersham Biosciences' Ettan™ DIGE technology. Scientists will use Impressionist's analysis capabilities to identify minimal sets of diagnostic marker proteins that are decisive for delineating cancer types into subclasses.

As one of the core cancer research institutes in Japan, the NCC cooperates closely with hospitals to conduct research in fundamental and applied sciences. These investigations aim to clarify the basic mechanisms of cancer development and to apply this knowledge to cancer prevention, diagnosis, and therapy.

"After completing an extensive evaluation of protein expression analysis software, we have chosen to work with Genedata because of their focus on providing scientifically validated computational systems for the drug discovery process and diagnostic applications in specific therapeutic areas," states Dr. Tadashi Kondo, Section Head of the Biology Division. "We are working with many different cancer samples from clinics as well as from cell lines. Therefore, we need sophisticated computational systems designed to handle this level of real-life complexity. Impressionist addresses the major challenges that we are facing in proteomics data analysis, namely data quality assessment, data standardization and biostatistical data analysis. Moreover, by providing ultra-high-throughput analysis capabilities, Impressionist overcomes the traditional drawback posed by data from 2D gels."

"We look forward to working with scientists at the NCC to meet the challenges in proteomics-based cancer diagnostics. Our comprehensive software systems for genome, gene and protein expression analysis provide the computational platform we need to develop application-specific solutions for cancer research, anti-infectives, and toxicogenomics. Close collaborations with leading scientific groups enable us to advance this strategy," adds Adesh Kaul, Head of Marketing & Business Development.

Record changed: 2011-12-21

Follow Us!

Top News

Upcoming Events

Associations

Partners

Genedata AG. (5/12/03). "Press Release: Japan’s National Cancer Center and Genedata Collaborate on Proteomics-based Cancer Diagnostic".

More documents for Genedata (Group)